Registration Dossier

Toxicological information

Acute Toxicity: oral

Currently viewing:

Administrative data

Endpoint:
acute toxicity: oral
Type of information:
experimental study
Adequacy of study:
key study
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
other: limited but acceptable documented study report which meets basic scientific principles

Data source

Reference
Reference Type:
study report
Title:
Unnamed
Year:
1978
Report date:
1978

Materials and methods

Principles of method if other than guideline:
other: acute oral toxicity study
GLP compliance:
no
Test type:
standard acute method

Test material

Constituent 1
Chemical structure
Reference substance name:
Sodium benzothiazol-2-yl sulphide
EC Number:
219-660-8
EC Name:
Sodium benzothiazol-2-yl sulphide
Cas Number:
2492-26-4
Molecular formula:
C7H4NS2.Na
IUPAC Name:
sodium 2-sulfanylidene-2,3-dihydro-1,3-benzothiazol-3-ide
Details on test material:
Merkaptobenzthiazol-Na (50% solution)

Test animals

Species:
rat
Strain:
Wistar
Sex:
male
Details on test animals or test system and environmental conditions:
male Wistar rats, SPF, weight 10- to 180 g, husbandry 5 animals per cage

Administration / exposure

Route of administration:
oral: gavage
Vehicle:
unchanged (no vehicle)
Details on oral exposure:
no further data
Doses:
0.5, 1.0, 2.0, 3.1, 3.5, 4.0, 5.0 ml /kg; (about 400, 800, 1600, 2480, 2800, 3200, 4000 mg/kg
densitiy ~ 1.25 g/cm³ (ECB IUCLID 2000)
No. of animals per sex per dose:
10 per dose
Control animals:
no
Details on study design:
no further data
Statistics:
LD50 according Fink und Hund, Arzneim.-Forsch 15, 624 (1965)

Results and discussion

Effect levels
Sex:
male
Dose descriptor:
LD50
Effect level:
2 100 mg/kg bw
Based on:
test mat.
Remarks on result:
other: clinical signs
Mortality:
dose 0.5 ml/kg, mortality 0/10; dose 1.0 ml/kg, mortality 1/10 rats; dose 2.0 ml/kg, mortality 2/10; dose 3.1 ml/kg, mortality 4/10; dose 3.5 ml/kg, mortality 8/10; dose 4.0 ml; mortality 8/10; dose 5.0 ml/kg, mortality 10/10
Clinical signs:
sedation, breathing disturbance, myoclonus
Body weight:
no data
Gross pathology:
no data
Other findings:
no data

Any other information on results incl. tables

Mortality occurred 3 min to 2 d after test substance application

Clinical signs observed: sedation, difficulties in respiration, myoclonus

 Dosis ml/kg  Calculated dosis in mg/kg (densitiy ~ 1.25 g/cm³)  Clinical signs  Mortality  Time of death
 0.5  400  0/10  0/10  -
 1.0  800  10/10  1/10  3 h
 2.0  1600  10/10  2/10  3 h
 3.1  2480  10/10  4/10 3 h 
 3.5  2800  10/10 8/10   2d
 4.0  3200  10/10  8/10  3 h
 5.0  4000  10/10  10/10  30 min

Applicant's summary and conclusion

Executive summary:

method: 10 male rats each received a single orale application per gavage of 0.5, 1.0, 2.0, 3.1, 3.5, 4.0, 5.0 ml test substance/kg bw, post-observation time 14 days

result: LD50 (male rats) = 2.63 ml/kg bw (~ 2100 mg/kg bw), clinical signs: sedation, breathing disturbance, myoclonus

reference: Loeser/Bayer AG (1978)